Plasmapheresis: Its use in multiple sclerosis and other demyelinating processes of the central nervous system. An observation study;Plasmaféresis: Su utilidad en la esclerosis múltiple y otros procesos desmielinizantes del sistema nervioso central. Estudio observacional

Revista de Neurologia

Volumn 37, Issue 10, 2003, Pages 917-926

  Meca Lallana, José E ^a   Rodriguez Hilario H ^a   Martinez Vidal S ^a   Saura Lujan I ^a   Carreton Ballester A ^a   Escribano Soriano, J B ^a   Martin Fernandez J ^a   Genoves Aleixandre A ^a   Mateo Bosch, E ^a   Fernandez Barreiro A ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

Author keywords

Demyelinization; Multiple sclerosis; Plasmapheresis; Progression; Severe relapses; Treatment

Indexed keywords

CORTICOSTEROID; METHYLPREDNISOLONE; PREDNISONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMYELINATING DISEASE; DISABILITY; DISEASE EXACERBATION; ENCEPHALOMYELITIS; FEMALE; FOLLOW UP; HUMAN; MALE; MULTIPLE SCLEROSIS; MYELITIS; OBSERVATION; PLASMAPHERESIS; RELAPSE; TREATMENT OUTCOME;

EID: 10744229678     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3710.2003369     Document Type: Article

References (36)

1. Noseworthy JH, Lucchinetti C, Rodríguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000; 343: 938-52.
2. Weinshenker BG. The natural history of multiple sclerosis. Neurol Clin 1995; 13: 119-46.
3. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-85.
4. Compston A, Coles A. Multiple Sclerosis. Lancet 2002; 359: 1221-31.
5. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343: 1430-8.
6. Bitsch A, Schuchardt J, Bunkowski S, Kuhlmann T, Brück W. Acute axonal injury in multiple sclerosis: correlation with demyelination and inflammation. Brain 2000; 123: 1174-83.
7. Alam SM, Kyriakides T, Lowden M, Newman PK. Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose. J Neurol Neurosurg Psychiatry 1993; 56: 1219-20.
8. Barnes D, Hughes RA, Morris RW, Wade-Jones O, Brown P, Britton T, et al. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 1997; 349: 902-6.
9. Dau PC, Petajan JH, Jonson KP, Panitch HS, Bornstein MB. Plasmapheresis in multiple sclerosis: preliminary findings. Neurology 1980; 30: 1028-203.
10. Dau PC. Plasmapheresis in acute multiple sclerosis: rationale and results. J Clin Apheresis 1991; 6: 200-4.
11. Weinshenker BG. Therapeutic plasma exchange for acute inflammatory demyelinating syndromes of the central nervous system. J Clin Apheresis 1999; 14: 144-8.
12. Vamvakas EC, Pineda A, Weinshenker BG. Meta-analysis of clinical studies of the efficacy of plasma exchange in the treatment of chronic progressive multiple sclerosis. J Clin Apheresis 1995; 10: 163-70.
13. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
14. Weinshenker BG. Plasma exchange for severe attacks of inflammatory demyelinating diseases of the central nervous system. J Clin Apheresis 2001; 16: 39-42.
15. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
16. Dau PC. Increased antibody production in peripheral blood mononuclear cells after plasma exchange therapy in multiple sclerosis. J Neuroimmunol 1995; 62: 197-200.
17. Hohlfeld R, Kerschensteiner M, Stadelmann C, Lassmann H, Wekerle H. The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis. J Neuroimmunol 2000; 107: 161-6.
18. Stadelmann C, Kerschensteiner M, Misgeld T, Bruck W, Hohlfeld R, Lassmann H. BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? Brain 2002; 125: 75-85.
19. Rodríguez M, Karnes WE, Bartleson JD, Pineda A. Plasmapheresis in acute episodes of fulminant CNS inflammatory demyelination. Neurology 1993; 43: 1100-4.
20. De Andrés C, Anaya F, Giménez-Roldán S. Tratamiento con plasma inmunoadsorción en brotes graves y prolongados de esclerosis múltiple maligna. Rev Neurol 2000; 30: 601-5.
21. Piddlesden SJ, Lassmann H, Zimprich F, Morgan BP, Linington C. The demyelinating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement. Am J Pathol 1993; 143: 555-64.
22. Storch MK, Piddlesden SJ, Haltia M, Iivanainen M, Morgan BP, Lassmann H. Multiple sclerosis: in situ evidence for antibody and complement mediated demyelination. Ann Neurol 1998; 43: 465-71.
23. García-Merino A, Persson MA, Ernerudh J, Díaz-Gil J, Olsson T. Serum and cerebrospinal fluid antibodies against myelin basic protein and their IgG subclass distribution in multiple sclerosis. J Neurol Neurosurg Psychiatry 1996; 49: 1066-70.
24. Raine CS, Cannella B, Hauser SL, Genain CP. Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: a case for antigen specific antibody mediation. Ann Neurol 1999; 46: 144-60.
25. Frequin ST, Barkhof F, Lamers KJ, Hommes OR, Borm GF. CSF myelin basic protein, IgG and IgM levels in 101 MS patients before and after treatment with high-dose intravenous methylprednisolone. Acta Neurol Scand 1992; 86: 291-7.
26. Sellebjerg F, Christiansen M, Garred P. MBP, anti-MBP and anti-PLP antibodies, and intrathecal complement activation in multiple sclerosis. Mult Scler 1998; 4: 127-31.
27. Zivadinov R, Rudick RA, De Masi R, Nasuelli D, Ukmar M, Pozzi-Mucelli RS, et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001; 57: 1239-47.
28. Fog T. The long-term treatment of multiple sclerosis with corticoids. Acta Neurol Scand 1965; 41 (Suppl): 473-84.
29. Crockard AD, Treacy MT, Droogan AG, Hawkins SA. CD4 subsets (CD45RA/RO) exhibit differences in proliferative responses, IL-2 and gamma interferon production during intravenous methylprednisolone treatment of multiple sclerosis. J Neurol 1996; 243: 475-81.
30. Wandinger KP, Wessel K, Trillenberg P, Heindl N, Kirchner H. Effect of high-dose methylprednisolone administration on immune functions in multiple sclerosis patients. Acta Neurol Scand 1998; 97: 359-65.
31. Gayo A, Mozo L, Suárez A, Tuñón A, Lahoz C, Gutiérrez C. Glucocorticoids increase IL-10 expression in multiple sclerosis patients with acute relapse. J Neuroimmunol 1998; 85: 122-30.
32. Droogan AG, Crockard AD, McMillan SA, Hawkins SA. Effects of intravenous methylprednisolone therapy on leukocyte and soluble adhesion molecule expression in MS. Neurology 1998; 50: 224-30.
33. Khatri BO. Therapeutic apheresis in multiple sclerosis and other central nervous system disorders. Ther Apher 2000; 4: 263-70.
34. Weiner HL, Dau PC, Khatri BO, Petajan JH, Birnbaum G, McQuillen MP, et al. Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis. Neurology 1989; 39: 1143-9.
35. Weinshenker BG. Plasma exchange for acute attacks of demyelinating disease: detecting a Lazarus effect. Ther Apher 2000; 4: 187-9.
36. Weinstein R. Therapeutic apheresis in neurological disorders. J Clin Apheresis 2000; 15: 74-128.